Nexsen proposes FlashDx joint venture as it broadens diagnostics pipeline
NXN: $0.160 -3.03% · MC: $32M
Nexsen signed a non-binding term sheet for a proposed 50:50 joint venture with FlashDx to develop and commercialise an enhanced GBS test, complementing its StrepSure program for different clinical settings. The company says it has identified changes intended to improve StrepSure ahead of a US regulatory submission, after suspending enrolment in its clinical study and ending assessment of the test in its current form; it reported no adverse safety signal or event. Nexsen also established a Hong Kong research base and added traumatic brain injury and neonatal sepsis programs to its diagnostics pipeline.

Comments